Chablani Priyanka, Nguyen Phuong, Pan Xueliang, Robinson Andrew, Walston Steve, Wu Christina, Frankel Wendy L, Chen Wei, Bekaii-Saab Tanios, Chakravarti Arnab, Wuthrick Evan, Williams Terence M
Department of Radiation Oncology.
Center for Biostatistics.
Am J Clin Oncol. 2017 Dec;40(6):561-568. doi: 10.1097/COC.0000000000000214.
The benefit of adjuvant chemotherapy in patients with locally advanced rectal cancer (LARC) treated with neoadjuvant chemoradiotherapy (nCRT) and surgery is controversial. We examined the association of perineural invasion (PNI) with outcomes to determine whether PNI could be used to risk-stratify patients.
We performed a retrospective study of 110 patients treated with nCRT and surgery for LARC at our institution from 2004 to 2011. Eighty-seven patients were identified in our final analysis. We evaluated the association of PNI with locoregional control, distant metastasis-free survival (DMFS), disease-free survival (DFS), and overall survival, using log-rank and Cox proportional hazard modeling.
Fourteen patients (16%) were PNI+ and 73 patients (84%) were PNI-. The median follow-up was 27 months (range, 0.9 to 84 mo). The median DMFS was 13.5 months for PNI+ and median not reached (>40 mo) for PNI- (P<0.0001). The median DFS was 13.5 months for PNI+ and 39.8 months for PNI- (P<0.0001). In a multivariate model including 7 pathologic variables, type of surgery, time to surgery from end of nCRT, and use of adjuvant chemotherapy, PNI remained a significant independent predictor of DMFS (hazard ratio 9.79; 95% confidence interval, 3.48-27.53; P<0.0001) and DFS (hazard ratio 5.72; 95% confidence interval, 2.2-14.9; P=0.0001).
For patients with LARC treated with nCRT, PNI found at the time of surgery is significantly associated with worse DMFS and DFS. Our data support testing the role of adjuvant chemotherapy in patients with PNI and perhaps other high-risk features.
新辅助放化疗(nCRT)联合手术治疗局部晚期直肠癌(LARC)患者时辅助化疗的获益存在争议。我们研究了神经周围侵犯(PNI)与预后的相关性,以确定PNI是否可用于对患者进行风险分层。
我们对2004年至2011年在本机构接受nCRT和手术治疗的110例LARC患者进行了回顾性研究。最终分析纳入87例患者。我们使用对数秩检验和Cox比例风险模型评估PNI与局部区域控制、无远处转移生存期(DMFS)、无病生存期(DFS)和总生存期的相关性。
14例患者(16%)为PNI阳性,73例患者(84%)为PNI阴性。中位随访时间为27个月(范围0.9至84个月)。PNI阳性患者的中位DMFS为13.5个月,PNI阴性患者未达到中位值(>40个月)(P<0.0001)。PNI阳性患者的中位DFS为13.5个月,PNI阴性患者为39.8个月(P<0.0001)。在一个包含7个病理变量、手术类型、nCRT结束至手术的时间以及辅助化疗使用情况的多变量模型中,PNI仍然是DMFS(风险比9.79;95%置信区间,3.48 - 27.53;P<0.0001)和DFS(风险比5.72;95%置信区间,2.2 - 14.9;P = 0.0001)的显著独立预测因素。
对于接受nCRT治疗的LARC患者,手术时发现的PNI与更差的DMFS和DFS显著相关。我们的数据支持测试辅助化疗在PNI及可能其他高危特征患者中的作用。